Johnson & Johnson Vision Care, Inc. to Acquire TearScience, Inc.
Johnson & Johnsonâs (NYSE:JNJ) Vision business said last Friday it inked a deal to acquire opthalmalogical medical device maker TearScience for an undisclosed amount.
Resarch Triangle Park, N.C.-based TearScience produces devices focused on treating meibomian gland dysfunction, a leading underlying cause of dry eye disease, Johnson & Johnson said.
TearScience has won FDA clearance for its office-based treatment of meibomian glands and treating MGD, with its devices available in the US and global markets, the company said.
Resarch Triangle Park, N.C.-based TearScience produces devices focused on treating meibomian gland dysfunction, a leading underlying cause of dry eye disease, Johnson & Johnson said.
TearScience has won FDA clearance for its office-based treatment of meibomian glands and treating MGD, with its devices available in the US and global markets, the company said.